# NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-Q for the period ended Mar 31, 2019

- Company: [NEUROONE MEDICAL TECHNOLOGIES Corp](/companies/nmtc.md) (CIK 1500198)
- Form: 10-Q
- Filed: 2019-05-10
- Accepted by EDGAR: May 10, 2019, 21:14 ET
- Period: 2019-03-31
- Accession: 0001213900-19-008306
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1500198/000121390019008306/f10q0319_neuroonemedi.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1500198/000121390019008306/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2019-01-01 to 2019-03-31 | $436.3k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2018-10-01 to 2019-03-31 | $645.5k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-01-01 to 2019-03-31 | −$1.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2018-10-01 to 2019-03-31 | −$2.6m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2019-01-01 to 2019-03-31 | −$2.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2018-10-01 to 2019-03-31 | −$3.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-01-01 to 2019-03-31 | −$0.20 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2018-10-01 to 2019-03-31 | −$0.34 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2018-10-01 to 2019-03-31 | −$2.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2019-03-31 | $2.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-03-31 | $2.4m | us-gaap:AssetsCurrent |
| Total assets | at 2019-03-31 | $2.6m | us-gaap:Assets |
| Current liabilities | at 2019-03-31 | $2.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-03-31 | $2.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-03-31 | $444.6k | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1500198/000121390019008306/f10q0319_neuroonemedi.htm

Filed May 10, 2019.
Source: SEC EDGAR, the filing index for accession 0001213900-19-008306. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.
